The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload

Nitric Oxide - Biology and Chemistry

Volumn 25, Issue 1, 2011, Pages 41-46

  Sverdlov, A L ^a   Ngo, D T M ^a   Nightingale, A K ^a,b   Rajendran, S ^a   Mishra, K ^a   Heresztyn, T ^a   Ritchie, R H ^c   Marwick, T H ^d   Frenneaux, M P ^e   Horowitz, J D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Diastolic function; Left ventricular mass; Nitric oxide; Vascular function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; CREATININE; GLYCERYL TRINITRATE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROCOLLAGEN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD VESSEL REACTIVITY; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CHOLESTEROL BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GENDER; HEART LEFT VENTRICLE DIASTOLIC DYSFUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; AGED, 80 AND OVER; ARGININE; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PREDICTIVE VALUE OF TESTS; SOFTWARE;

EID: 79958137814     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2011.04.009     Document Type: Article

References (41)

1. N. Frey, E.N. Olson, Cardiac hypertrophy: the good, the bad, and the ugly, Annu. Rev. Physiol. 65 (2003) 45-79.
2. W. Grossman, D. Jones, L.P. McLaurin, Wall stress and patterns of hypertrophy in the human left ventricle, J. Clin. Invest. 56 (1975) 56-64.
3. E. Grossman, F.H. Messerli, Diabetic and hypertensive heart disease, Ann. Intern. Med. 125 (1996) 304-310. (Pubitemid 126449277)
4. B.R. Cowan, A.A. Young, Left ventricular hypertrophy and renin-angiotensin system blockade, Curr. Hypertens. Rep. 11 (2009) 167-172.
5. G.H. Gibbons, Endothelial function as a determinant of vascular function and structure: a new therapeutic target, Am. J. Cardiol. 79 (1997) 3-8.
6. R.A. Kelly, J.L. Balligand, T.W. Smith, Nitric oxide and cardiac function, Circ. Res. 79 (1996) 363-380.
7. L.E. Spieker, T.F. Luscher, Protection of endothelial function, Handb. Exp. Pharmacol. (2005) 619-644.
8. D. Behrendt, P. Ganz, Endothelial function. From vascular biology to clinical applications, Am. J. Cardiol. 90 (2002) 40L-48L.
9. R.H. Ritchie, J.C. Irvine, A.C. Rosenkranz, R. Patel, I.R. Wendt, J.D. Horowitz, B.K. Kemp-Harper, Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO? and beyond, Pharmacol. Ther. 124 (2009) 279-300.
10. H. Shimokawa, M. Tsutsui, Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice, Pflugers Arch. 459 (2010) 959-967.
11. A. Calderone, C.M. Thaik, N. Takahashi, D.L. Chang, W.S. Colucci, Nitric oxide atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts, J. Clin. Invest. 101 (1998) 812-818.
12. J.C. Irvine, R.H. Ritchie, J.L. Favaloro, K.L. Andrews, R.E. Widdop, B.K. Kemp-Harper, Nitroxyl (HNO): the Cinderella of the nitric oxide story, Trends Pharmacol. Sci. 29 (2008) 601-608.
13. R.H. Ritchie, Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance, Heart Lung Circ. 18 (2009) 11-18.
14. R.H. Ritchie, R.J. Schiebinger, M.C. LaPointe, J.D. Marsh, Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide, Am. J. Physiol. 275 (1998) H1370-1374.
15. K.C. Wollert, H. Drexler, Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis, Heart Fail. Rev. 7 (2002) 317-325.
16. F. Ichinose, K.D. Bloch, J.C. Wu, R. Hataishi, H.T. Aretz, M.H. Picard, M. Scherrer-Crosbie, Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency, Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1070-1075.
17. K. Sydow, T. Munzel, A.D. MA, Oxidative stress, Atherosclerosis Suppl. 4 (2003) 41-51.
18. R.H. Boger, S.M. Bode-Boger, W. Thiele, W. Junker, K. Alexander, J.C. Frolich, Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease, Circulation 95 (1997) 2068-2074. (Pubitemid 27184275)
19. R.H. Boger, The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor, Cardiovasc. Res. 59 (2003) 824-833.
20. C. Zoccali, F. Mallamaci, R. Maas, F.A. Benedetto, G. Tripepi, L.S. Malatino, A. Cataliotti, I. Bellanuova, R. Boger, Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients, Kidney Int. 62 (2002) 339-345.
21. F.A. Ebinc, Y. Erten, H. Ebinc, H. Pasaoglu, C. Demirtas, G. Tacoy, R. Mutluay, E. Koc, U. Derici, K.A. Reis, M. Bali, T. Arinsoy, S. Sindel, The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients, Ren. Fail. 30 (2008) 401-406. (Pubitemid 351868689)
22. W. Lieb, R.A. Benndorf, E.J. Benjamin, L.M. Sullivan, R. Maas, V. Xanthakis, E. Schwedhelm, J. Aragam, F. Schulze, R.H. Boger, R.S. Vasan, Plasma asymmetric dimethylarginine L-arginine and left ventricular structure and function in a community-based sample, Atherosclerosis 204 (2009) 282-287.
23. G.A. Silberman, T.H. Fan, H. Liu, Z. Jiao, H.D. Xiao, J.D. Lovelock, B.M. Boulden, J. Widder, S. Fredd, K.E. Bernstein, B.M. Wolska, S. Dikalov, D.G. Harrison, S.C. Dudley Jr., Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction, Circulation 121 (2010) 519-528.
24. Y.Y. Chirkov, J.D. Horowitz, Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?, Pharmacol Ther. 116 (2007) 287-305. (Pubitemid 47451509)
25. G. de Simone, R.B. Devereux, S.R. Daniels, M.J. Koren, R.A. Meyer, J.H. Laragh, Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk, J. Am. Coll. Cardiol. 25 (1995) 1056-1062.
26. S.H. Park, C. Shub, T.P. Nobrega, K.R. Bailey, J.B. Seward, Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography, J. Am. Soc. Echocardiogr. 9 (1996) 119-128.
27. T. Heresztyn, M.I. Worthley, J.D. Horowitz, Determination of L-arginine and NG NG - and NG, NG′-dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Fluor fluorescent derivatives, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 805 (2004) 325-329.
28. I.B. Wilkinson, J.R. Cockcroft, D.J. Webb, Pulse wave analysis and arterial stiffness, J. Cardiovasc. Pharmacol. 32 (Suppl. 3) (1998) S33-37.
29. X.F. Figueroa, I. Poblete, R. Fernandez, C. Pedemonte, V. Cortes, J.P. Huidobro-Toro, NO production and eNOS phosphorylation induced by epinephrine through the activation of beta-adrenoceptors, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H134-143.
30. C.S. Hayward, M. Kraidly, C.M. Webb, P. Collins, Assessment of endothelial function using peripheral waveform analysis: a clinical application, J. Am. Coll. Cardiol. 40 (2002) 521-528. (Pubitemid 34833170)
31. I.B. Wilkinson, A. Qasem, C.M. McEniery, D.J. Webb, A.P. Avolio, J.R. Cockcroft, Nitric oxide regulates local arterial distensibility in vivo, Circulation 105 (2002) 213-217. (Pubitemid 34084321)
32. I.B. Wilkinson, I.R. Hall, H. MacCallum, I.S. Mackenzie, C.M. McEniery, C.M. McEniery, B.J. Van der Arend, Y.E. Shu, L.S. MacKay, C.M. Webb, J.R. Cockcroft, Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function, Arterioscler. Thromb. Vasc. Biol. 22 (2002) 147-152.
33. J.J. Oliver, A. Bowler, Q. Beudeker, T. Cate, D.J. Webb, Dose-response relationship of sublingual nitroglycerin with brachial artery dilatation and change in central and peripheral augmentation index, Clin. Pharmacol. Ther. 77 (2005) 337-338. (Pubitemid 40470390)
34. P. Segers, N. Stergiopulos, N. Westerhof, Quantification of the contribution of cardiac and arterial remodeling to hypertension, Hypertension 36 (2000) 760-765.
35. P.M. Mottram, T.H. Marwick, Assessment of diastolic function: what the general cardiologist needs to know, Heart 91 (2005) 681-695. (Pubitemid 40559369)
36. B.A. Borlaug, V. Melenovsky, M.M. Redfield, K. Kessler, H.J. Chang, T.P. Abraham, D.A. Kass, Impact of arterial load and loading sequence on left ventricular tissue velocities in humans, J. Am. Coll. Cardiol. 50 (2007) 1570-1577. (Pubitemid 47532334)
37. E. Kaplinsky, Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality, Cardiovasc. Drugs Ther. 8 (Suppl. 3) (1994) 549-556.
38. J.G. Bronzwaer, W.J. Paulus, Nitric oxide: the missing lusitrope in failing myocardium, Eur. Heart J. 29 (2008) 2453-2455.
39. W.J. Paulus, A.M. Shah, Cardiac diastolic function, Cardiovasc Res 43 (1999) 595-606.
40. C.G. Brilla, R.C. Funck, H. Rupp, Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease, Circulation 102 (2000) 1388-1393.
41. W.H. Wilson Tang, W. Tong, K. Shrestha, Z. Wang, B.S. Levison, B. Delfraino, B. Hu, R.W. Troughton, A.L. Klein, S.L. Hazen, Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure, Eur Heart J 29 (2008) 2506-2513.